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Abstract: Background: Impulse-control behaviors (ICBs) are increasingly recognized in Parkinson’s disease
(PD) as drug-related effects of dopaminergic mediation that occur in 15% to 35% of patients with PD. The
authors describe the design and evaluation of a new, clinician-rated severity scale for the assessment of
syndromal and subsyndromal forms of impulse-control disorders (ICDs), simple (punding) and complex
(hobbyism) repetitive behaviors, and compulsive overuse of medication (dopamine dysregulation syndrome).
Methods: The Parkinson’s Impulse-Control Scale (PICS), the first PD-specific, semistructured interview to
cover the full range of PD-related ICBs, is described along with initial evidence on its clinimetric properties
including interrater reliability, discriminant validity and sensitivity to change. A convenience sample of PD
patients with ICBs and those without were administered a semistructured interview (n = 92).
Results: The scale distinguished between those with and without clinically detected ICBs and between patients
with syndromal ICD and subsyndromal ICB (receiver operating characteristic areas under the curve, 92%–95%).
Cutoff values were suggested, and substantial agreement was reported on weighted kappa (Κ) values for
clinician-clinician rating of severity (Κ = 0.92). Significant improvements were detected on the scale after a
randomized controlled trial of cognitive-behavioral therapy andmedication adjustment (t[22] = 5.47; P < 0.001).
Conclusions: The PICS appears to be a reliable measure of the full range of PD ICBs with good levels of
interrater reliability. It may provide a useful measure to assess the severity of ICBs and monitor change in
clinical and research settings; although, given the specialized centers used for recruitment of this sample,
further psychometric evaluation is required.
Impulse-control disorder (ICD) in Parkinson’s disease (PD)
describes problematic behaviors that include pathological
gambling, compulsive shopping, compulsive eating, altered
sexual behavior, hobbyism, punding, and dopamine medica-
tion overuse (dopamine dysregulation syndrome [DDS]).1–3
Such problems occur in 15% to 35% of people with PD4,5
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and are variably associated with insight.6 Where they impact
significantly on social and occupational functioning, they
warrant the term “disorder,” but they lie on a continuum of
severity, suggesting that a dimensional approach to the assessment
of impulse-control behaviors (ICBs) may be most appropriate.2
A variety of generic and PD-specific ICD/ICB screening
tools exist.7–10 The Questionnaire for Impulsive-Compulsive
Disorders in Parkinson’s Disease (QUIP) is the most commonly
used, validated, self-report screening tool and assesses the ICDs
listed above.11 A corresponding rating scale (QUIP-RS) is avail-
able to rate the severity of the same behaviors and provide a
measure of change over time.12
Self-report scales have considerable utility in research and
clinical practice but may have limited usefulness where the indi-
vidual lacks insight or seeks to minimize aspects of the behav-
ior.13 Clinician-rated instruments based on semistructured
interviews with operationalized scoring criteria can provide a
more detailed quantitative assessment in some settings. Such an
assessment can also aid in the clinical decision regarding
whether the behaviors have an impact on social and occupa-
tional functioning sufficient for caseness as a Diagnostic and
Statistical Manual of Mental Disorders, fourth edition (DSM-IV) (or
DSM-aligned) disorder. To our knowledge, there are no
PD-specific, semistructured clinical assessment tools designed to
cover all of the most common ICBs.
Recently, we published results from a randomized controlled
trial of a cognitive-behavioral intervention for the management
of ICBs in PD.14,15 A new clinician-rated scale—the Parkinson’s
Impulse-Control Scale (PICS) (formerly known as the Impulse-
Control Behavior Severity Scale)—was developed for the trial
and was used as a secondary outcome. The QUIP-RS was not
available at the time. The PICS was found to be sensitive to change
in ICB severity resulting from treatment. Here, we report on the
scales’ validity, reliability, and sensitivity to change after routine
medical management (medication adjustment) and the above-
mentioned cognitive-behavioral therapy (CBT) intervention.
Materials and Methods
Scale Description
PICS
The PICS is a clinician-rated scale based on a semistructured
interview that measures both the intensity of each ICB (indi-
cated by frequency and scale of the behavior) and its individual
and social impact, which are combined to provide an index of
severity. It covers 7 ICBs; gambling, shopping, eating, hyper-
sexuality, simple (punding) and complex (hobbyism) repetitive
behaviors, and compulsive overuse of medication (DDS).2,4
For illustration, the questions and scoring criteria for the
Gambling Behavior scale of the PICS are provided online (see
online supporting information). A copy of the full PICS is
available from the authors on request. Each ICB subscale com-
prises an initial 3-item screening questionnaire (yes/no
responses) to determine: (1) the presence of any ICBs in the
preceding month; (2) the relation between any behavior and
PD; and (3) whether they, or their carer/partner, believe that
the behavior has worsened since starting medications (poten-
tially minimizing underreporting/denial of symptoms).
These screening questions were developed based on a focus
group, a review of existing scales (Evans et al., unpublished
results), and discussions with experts who had an interest in
ICB. The timeframe of 1 month was selected as sufficient to
detect infrequent ICBs while still allowing the scale to measure
change. The use of screening questions was designed to save
time, because no ICB or preexisting ICB that was not plausibly
linked to PD or medication use would not be further assessed.
If, on the basis of this information, the clinician deems the
behavior to be present and PD-related, then further questions
are asked for that ICB. Structured questions specific to the
behavior are used to elicit information related to its intensity
and impact on the individual and others. This quantitative and
qualitative information is recorded but not scored. Rather, the
information, combined with that from other sources (e.g, collat-
eral history), informs the final clinical rating of behavior on an
operationalized scale from 1 to 4 for intensity and from 1 to 3
for impact. A score of 0 is assigned when the ICB is absent.
For each ICB, the clinician-rated intensity and impact scores
are multiplied to give a single severity score between 0 and 12.
Finally, the clinician is able to indicate their confidence based
on the information available. A total severity score can be
derived as the sum of the 7 ICBs with a range from 0 to 84
(higher scores denote greater severity).
When eliciting information, the interview enquires about the
behavior both “on average” and at its maximum. These
extremes, even if infrequent, are important in forming clinical
judgements about intensity and impact. For example, gambling
losses may be typically modest but large on occasions. Ratings
also take into account the individual context of the behavior,
particularly for impact. For example, an individual may place
frequent bets but have a large income. Therefore, the behavior
will be seen as having limited impact but will be important for
meaningful clinical interpretation.
The screening questions can be completed in less than
2 minutes if there are no ICBs. For those with 2 or 3 ICBs,
the scale typically can be completed in 5 to 10 minutes.
Administration and scoring require a degree of training or
clinical familiarity with ICBs in PD.
Participants
In total, 92 patients with PD were interviewed face-to-face or
by phone (Table 1). Patients with and without known ICBs
were purposely sampled from a variety of sources to provide a
group with problems spanning a wide range of severities. We
assessed the eligibility of 45 patients who had clinically evident
ICBs for possible inclusion in our randomized controlled trial.14
An additional 41 participants were recruited as a convenience
sample from King’s College Hospital Movement Disorder
Service and comprised patients with known ICBs as well as
patients thought to have no ICB. A further 6 participants
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responded to an advert posted on Parkinsons.org.uk (British-
based) and PatientsLikeMe.com (US-based). One author (D.O.)
performed baseline assessments on all patients and repeat mea-
sures at 6 months. An additional 12 patients were independently
assessed by another author (J.M.) for levels of agreement.
Patients with ICBs who had not had a trial of dopamine agonist
reduction were reassessed at 6 months after an attempted grad-
ual tapering of medication by their treating clinician.
Exclusion criteria were Standardized Mini-Mental State
Examination16 scores < 24 (for face-to-face assessments) or
Telephone Interview of Cognitive Status-Modified17 scores <
19 (for telephone assessments). The study was approved by the
National Research Ethics Service (ref no: 10/H0716/46).
Informed consent was obtained from both patients and care-
givers.
Clinimetric Assessment
Data quality was assessed (including missing data), and a 5%
value for noncomputable or missing data was deemed acceptable
as the limit.18 The purposeful (nonrandom) nature of the sample
selection meant that estimates of scale-skewness and floor
and ceiling effects could not be meaningfully computed.19
Acceptability of the scale was judged on the basis of participant
willingness to complete the assessment and answer all questions.
Discriminant validity was assessed by comparing PICS scores
between patients with and without evidence of a current or
recent ICB. Presence of an ICB was determined based on the
QUIP11 and additional questions to assess DSM-IV criteria for
pathological gambling, binge eating disorder, Voon’s criteria for
hypersexuality, and McElroy’s criteria for shopping.8,20,21
For patients who had an ICB, we assessed the ability of the
PICS to discriminate between those who met criteria for a
syndromal ICD and those who did not. This assessment was
restricted to eating, sex, gambling, and shopping where opera-
tionalized diagnostic criteria exist. Symptoms that did not meet
full diagnostic criteria for each of the disorders were labeled as
subsyndromal; then, the ability of the PICS to discriminate
validity was assessed for each behavior/disorder individually. A
receiver operating characteristics analysis provided the area
under the curve and optimal cutoff scores to determine syndro-
mal disorder.
Responsiveness to change was assessed in 2 subgroups using a
paired t test for each sample. The first was the total sample of
patients (N = 41) who completed CBT for the management of
their ICB. Patients were assessed before and at the end of treat-
ment (fixed time point, 6 months). The second subgroup was a
sample of patients (N = 23) identified with an incident ICB
who were then managed medically by adjustment of their
antiparkinsonian medication. Patients were assessed before
adjustment and after 6 months.
A limited assessment of interrater reliability was based on 12
patients who were receiving stable treatment by independent
ratings approximately 1 month apart. These assessments were
performed by 2 authors (J.M. and D.O.). Test-retest reliability
was assessed on the subsample of CBT waitlist control patients
(n = 17) who were receiving stable antiparkinsonian treatment
6 months after initial assessment. Quadratic weighted kappa (Κ)
values were used for both measures of reliability.
Results
All interviews were successfully completed in full with no refu-
sals to answer questions or other sources of missing data. Base-
line characteristics are presented in Table 1. There were no
significant differences between groups based on demographic or
clinical characteristics. Of the 92 patients assessed, 28 (25%)
screened positive for 1 ICD, 18 (16%) screened positive for 2
ICDs, and 9 (8%) screened positive for 3 ICDs. Six patients had
hobbyism, punding, or DDS. ICBs were further identified in 4
patients who were referred by clinicians as part of the non-ICB
convenience sample (all had hypersexuality).
The frequencies of ICBs and PICS subscores for those who
scored positive and negative on the QUIP are reported in
Table 2. PICS screening questions confirmed the presence of a
QUIP-indicated ICB in all patients and identified an additional
19 patients who had eating, sex, gambling, and DDS ICBs.
TABLE 1 Demographic and Clinical Information (N = 92)
Mean  SD or No. of Patients (%)
ICB Group,
n = 67
Non-ICB Group,
n = 25
Patient Characteristics
Age, y 59.6  8.7 62.5  10.9
Men 46 (69) 17 (68)
Duration of PD, y 10.2  6.0 9.0  6.3
Duration of ICB, y 4.1  3.8 —
sMMSE total score* 28.3  2.2 28.6  1.3
TICS-M total score:
Range, 0–39
†
21.1  4.2 26.8  2.8
Marital status
Single 3 (5) 3 (12)
Married/cohabiting 47 (73) 18 (72)
Separated/divorced 6 (8) 3 (12)
Widowed 9 (14) 1 (4)
Ethnic origin
White 63 (94) 23 (92)
Other 4 (6) 2 (8)
Education
‡
Left school at age <14 y 6 (10) 0 (0)
Left school
at age 14–15 y
21 (33.9) 5 (20)
Left school at age >16 y 35 (57) 20 (80)
Medication
UPDRS
UPDRS-III
§
29.7  13.9 29  15.5
UPDRS-IV
||
7.8  4.4 5.3  5.2
Hoehn and Yahr 2.0  1.2 2.4  1.2
*MMSE: ICB group, n = 58; non-ICB group, n = 17.
†TICS-M: ICB group, n = 8; non-ICB group, n = 6.
‡Education: ICB group, n = 62.
§UPDRS: ICB group, n = 53; non-ICB group, n = 18.
||ICB group, n = 56; non-ICB group, n = 18.
SD, standard deviation; ICB, impulse-control behavior; PD, Parkin-
son’s disease; sMMSE, Standardized Mini-Mental State Examination;
TICS-M, Telephone Interview of Cognitive Status-Modified; UPDRS,
Unified Parkinson’s Disease Rating Scale; UPDRS-III, UPDRS part 3
(clinician-scored monitored motor evaluation); UPDRS-IV, UPDRS
part 4 (complications of therapy).
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Interviewer confidence in accuracy of the ratings for the scale
was “acceptable” in 59%, defined as probably reflecting the
approximate nature and scale of the problem; and “good” in
41%, defined as likely to reflect the true nature and scale of the
problem (usually based on informant corroboration).
Discriminant Validity
The mean  standard deviation (SD) total PICS score for those
who screened positive for 1 or more ICBs (N = 67) was
8.9  5.7 (range, 1–26) compared with 0  0 for those with-
out an ICB (N = 25). Further analysis was restricted to those
patients who screened positive for an ICB on the PICS.
Mean  SD PICS scores across the 4 index ICBs were sig-
nificantly higher for those who met the criteria for syndromal
ICD (6.6  3.0; range, 3–12) compared with those who had
subsyndromal ICD (1.7  0.8; range, 1–4; t[90] = 9.4;
P < 0.05). Receiver operating characteristics analysis showed
high areas under the curve from 92% to 95% (Table 3).
Responsiveness to Change
A subset of 23 patients was examined before and after adjustment
(typically reduction) of the antiparkinsonian medication. Dopamine
agonist was discontinued in 40% of patients. The initial mean  SD
levodopa-equivalent dose (LEDD) was 1207.8  612.6 mg, with
reduction to a mean of 922.6  525.2 mg (the dopamine agonist
LEDD was reduced from 214.6  38.4 mg to 142.8  127.9 mg).
The mean  SD total PICS score fell from 10.4  5.8 before dose
reduction to 3.1  3.1 after reduction (t[22] = 5.47; P < 0.001;
effect size, 1.6). In addition, the scale proved sensitive to change in
those who underwent treatment in the context of a psychosocial
intervention as reported elsewhere.14
Interrater and Test-retest
Reliability
Agreement for interrater reliability and for test-retest is shown
in Table 4. The 2 clinicians showed substantial agreement on
the 12 participants assessed. For those with ICBs who were on
the waiting list for the psychosocial intervention (n = 17), PICS
total scores at baseline and at 26 weeks were moderately associ-
ated with baseline scores. Mean scores  SD for individual
ICBs were 4.50  2.9 at baseline and 3.68  2.8 at 6 months
(t[16] = 1.13; P = 0.27).
Discussion
The PICS is a brief, clinician-rated screening and severity tool
and provides a means of gathering comprehensive data, allowing
an assessment of the intensity and impact of a wide range of
ICBs common in PD. The preliminary results presented suggest
TABLE 2 Parkinson’s Impulse-Control Scale Scores by Problem for Participants Scoring >0 on Each Subscale
Variable No. (%)* PICS Subscale
Score: Mean  SD
QUIP No.
Positive:Negative
Syndromal
ICB: No. (%)*
Mean  SD Score [Scoring Range]
Syndromal Subsyndromal
Eating 31 (26) 3.4  2.5 21:10 14 (45) 5.7  2.1 [4–12] 1.4  0.6 [1–3]
Sex 28 (24) 6.4  4.1 24: 4 21 (75) 8.4  3.4 [3–12] 1.9  0.7 [1–3]
Gambling 16 (14) 5.5  3.1 14: 2 12 (75) 6.8  2.5 [4–12] 1.8  1.0 [1–3]
Shopping 16 (14) 3.8  2.2 16:0 8 (50) 5.4  2.0 [3–9] 2.3  1.0 [1–4]
Punding 4 (3) 5.3  2.5 4:0 NA — —
Hobbyism 8 (10) 5.5  1.9 8:0 NA — —
DDS/off period
dysphoria
9 (8) 6.4  2.1 6:3 NA — —
Total 112 4.9  3.2 81:19 56 (62) 6.6  3.0 [3–12] 1.7  0.8 [1–4]
*Values are shown as the percentage of those who had 1 or more impulse-control behavior(s).
SD, standard deviation; PICS, Parkinson’s Impulse-Control Scale; QUIP, Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s
Disease; ICB, impulse-control behaviors; NA, not accessible; DDS, dopamine dysregulation syndrome.
TABLE 3 Discriminant Validity of the Parkinson’s Impulse-Control Scale (N = 92)*
Receiver Operating Characteristics
Subscale ≥1 >1 >2 >3 >4 >6 >8 >9 >12
Eating (AUC = 0.981)
Sensitivity, % 100 100 100 93
†
73 20 13 — 0
Specificity, % 0 56 89 89 100 100 100 — 100
Sex (AUC = 0.928)
Sensitivity, % 100 95 91
†
73 — 59 — 27 0
Specificity, % 0 33 83 100 — 100 — 100 100
Gambling (AUC = 0.982)
Sensitivity,% 100 100 100 100 82
†
36 — 9 0
Specificity, % 0 40 60 80 100 100 — 100 100
Shopping (AUC = 0.944)
Sensitivity, % 100 100 100 80
†
70 30 20 10 0
Specificity, % 0 25 63 87.5 100 100 100 100 100
*The table shows area under the curve (AUC) values for each subscale.
†The optimal cutoff with both sensitivity and specificity ≥80% for each subscale.
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that the scale is practical to use, acceptable to patients, and
demonstrates a degree of reliability and sensitivity to change.
The PICS offers an alternative or adjunct to the recently
published QUIP-RS,12 from which it differs in a numbers of
respects. The mode of administration of the scale (self-report or
clinician-rated) is important, with each method conferring dif-
ferent advantages: economy for the QUIP-RS and the ability to
make clinically informed ratings for the PICS, but with a cost
to time and the need for an experienced rater. The QUIP-RS
also focusses attention to those behaviors that the patient identi-
fies as problematic and uses frequency as the main indicator or
severity. This risks missing instances in which a patient mini-
mizes the impact of an ICB or underestimates a behavior that is
relatively infrequent but intense. For the PICS, observation of
behavior is recorded regardless of whether it is believed to be a
problem, and this is followed by an exploration of typical and
extreme variation in behavior to make a clinically informed
decision. It can also be combined with other sources when
making overall ratings. Similarly, the PICS can better deter-
mine, from the outset, whether the ICB may be a preexisting
condition independent of PD or whether it has emerged or
worsened with PD and its treatment. Ultimately, choice
between the 2 scales in research and clinical practice will
depend on the purpose of the assessment. The 2 forms of
administration may suggest the use of both measures to provide
complementary evidence on severity.
This study offers preliminary cutoffs for the PICS subscales
for identifying syndromal forms of the behaviors with high
levels of specificity, but these will need confirmation with larger
samples. The high positive, and low negative likelihood ratios
in each ICBs signify the respective probabilities of having or
not having the disorder at a clinical cutoff point. Optimal cut-
offs for scales where a gold-standard syndromal diagnosis is not
available remain to be determined but a figure of 4 or 5 is sug-
gested as appropriate in the first instance. The PICS and sub-
scales also proved sensitive to change in those who had a
reduction in their medication. This is the usual clinical
approach to management of this range of conditions and hence
the scale may have utility in day-to-day clinical monitoring of
ICBs and ICDs. The identification of previously clinically
unrecognized ICBs suggests that the systematic format of the
interview is acceptable to patients who report behaviors judged
(clinically) to indicate an ICB.
In relation to DDS, the scale takes a broad approach to iden-
tification and assessment and thus may produce different
estimates of prevalence and severity than other measures. Our
conceptualization of DDS includes not only the small propor-
tion of individuals who medicate to seek a medication high3
but also those who develop a phobic or anticipatory avoidance
of being off, losing control of their daily regimen, with “rescue”
medications to deleterious effect.2
The preliminary interrater reliability results suggest that the
ratings for intensity and impact allow agreement when descrip-
tions of ICBs are sufficiently operationalized. The lower test-
retest reliability may indicate a limitation of the scale but could
also reflect true clinical variation in the severity of the behaviors
during the interval.
Nonetheless, the development of the scale has several limita-
tions. Many of the diagnostic criteria for the PD ICBs in them-
selves lack validation, whereas we lack operationalized criteria
for punding, hobbyism, and DDS. As such, the focus of the
present study was not on validation of the tool for screening of
ICDs (the screening questions were used to reduce the time
burden of the assessment). In addition, the scale may need to be
adapted for use outside the United Kingdom, particularly where
population rates and cultural norms surrounding the behaviors
may differ. As with many multidimensional scale measures of
both frequency and intensity of a behavior, a patient with 1
very severe ICD theoretically could score the same as someone
with 2 or 3 milder ICDs (not affecting function). In practice,
we observed quite the opposite: the patients tended to have 1
dominant ICB or several minor ICBs that scored a low aggre-
gate, which was supported by our findings on mean scores for
syndromal and subsyndromal ICBs. Finally, given the unblinded
nature of the assessments and the purposeful sampling of ICBs,
caution is necessary in relation to sensitivity to change.
Subject to further use and confirmation of its metric proper-
ties, we suggest that the scale has a role in the assessment of
ICBs in clinical and research settings. Further work will be
required to evaluate the scale with a variety of raters who are
less familiar with the scale in relation to the QUIP-RS and in
nontertiary-level settings.
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